Smoking (Tobacco) AddictionPhase 3PREVENTNCT05102123
PeRiopEratiVE SmokiNg CessaTion Trial
A Phase 3 study testing Cytisine and Video Messaging in people with Smoking (Tobacco) Addiction and Smoking Cessation, run by Population Health Research Institute at 4 sites in Canada.
Trial summary
PREVENT is a multicentre, 2x2 factorial, randomized clinical trial that aims to determine the effect of cytisine versus placebo, as well as the effect of video messaging to support smoking cessation versus standard of care in perioperative patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Smoking (Tobacco) Addiction, Smoking Cessation
- What is being tested?
- Cytisine and Video Messaging
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,720 participants
- Where
- 4 sitesCanada
- Study dates
- 15 Jan 2024to 1 Jan 2027
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- are ≥18 years of age
- are scheduled to undergo surgery within 28 days
- are a current smoker and not currently using any smoking cessation treatment and,
- have a smart mobile phone with an active, up to date data plan and with internet access
- provide informed consent to participate.
Who cannot join
- are pregnant or breastfeeding or expecting to become pregnant during the study follow-up period
- are deemed unreliable for study procedures or follow-up
- have a documented allergic reaction to cytisine, or its components (non-medicinal ingredients) or to the non-medicinal ingredients of the placebo.
- had myocardial infarction, unstable angina, or stroke/transient ischemic attack within the preceding 2 weeks.
- will have surgery with expected nil intake by mouth for 2 or more days
- have previously participated in PREVENT
- have a known diagnosis of untreated pheochromocytoma; Schizophrenia/bipolar psychiatric illness and currently psychotic; currently having suicidal ideation or risk of suicide as determined by the site physician, known history of moderate to severe depression; currently uncontrolled severe hypertension (≥180/120 mmHg) despite treatment; known history of uncontrolled hyperthyroidism (thyrotoxicosis), severe renal impairment i.e., creatinine clearance of less than 30 ml per minute (Cockcroft- Gault equation) or receiving long-term dialysis, or known diagnosis of severe liver disease as determined by the site physician or documented in the clinical history.
Trial locations and contacts
4 sites in 1 country.
Canada4 sites
Hamilton General Hospital
Hamilton, Ontario, L8L 2X2
Juravinski Cancer Centre
Hamilton, Ontario, L8V 5C2
Kingston Health Science Centre with its research institute Kingston General Health Research Institute
Kingston, Ontario, K7L 3N6
Lawson Health Research Institute: London Health Sciences Centre Research Inc. and the Lawson Research Institute
London, Ontario, N6C 2R5
About this study
PREVENT is a multicentre, 2x2 factorial, randomized clinical trial that aims to determine the effect of cytisine versus placebo, as well as the effect of video messaging to support smoking cessation versus standard of care in perioperative patients. This trial aims to investigate the effects of cytisine and text messaging on 6-month continuous abstinence rates. PREVENT will also assess secondary outcomes at 30 days, 56 days and 6 months post-randomization: 7-day point prevalence abstinence, urge to smoke, time to first lapse, time to relapse, number of cigarettes smoking if still smoking, pulmonary complications, vascular complications, wound and infectious complications, stroke, time in hospital and acute hospital care.
- Conditions
- Smoking (Tobacco) Addiction, Smoking Cessation
- Being tested
- Cytisine, Video Messaging
- Medical subject headings
- Smoking, Behavior, Addictive, Smoking Cessation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CytisineDrug
Listed as a natural health product in Canada, cytisine is utilized to aid in smoking cessation
Video MessagingBehavioural
Supportive messaging utilizing a video messaging platform to encourage patients to abstain from smoking throughout the treatment period.
| Study group | Role | What they receive |
|---|---|---|
| Cytisine and Video Messaging | Experimental | Administration of cytisine (pharmaceutical support) to patients on a set dose schedule with behavioural support through video messaging. Receives: Drug: Cytisine; Behavioral: Video Messaging |
| Placebo and Video Messaging | Placebo comparator | Administration of placebo (inactive drug) to patients on a set dose schedule with behavioural support through video messaging. Receives: Behavioral: Video Messaging |
| Cytisine and No Video Messaging | Active comparator | Administration of cytisine (pharmaceutical support) to patients on a set dose schedule with behavioural support according to standard care such as a phone number for a self-help line. Receives: Drug: Cytisine |
| Placebo and No Video Messaging | No intervention | Administration of placebo (inactive drug) to patients on a set dose schedule behavioural support according to standard care such as a phone number for a self-help line. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Smoking Cessation
complete abstinence (smoking not more than 5 cigarettes) beginning on day 5 post randomization and lasting until the assessment at 6 months post-randomization with biochemical verification for those who report abstinence, using exhaled breath carbon monoxide (cut-off <10 parts per million [ppm]) measured with a carbon monoxide (CO) monitor
Measured: 6 months
Secondary outcomes (18)
7-day point-prevalence abstinence at 30 days
Self-report of not smoking cigarettes [not even a puff] in the 7 days before the 30-day follow-up
Measured: 30 days
7-day point-prevalence abstinence at 56 days
Self-report of not smoking cigarettes [not even a puff] in the 7 days before the 56-day follow-up
Measured: 56-days
7-day point-prevalence abstinence at 6-months
Self-report of not smoking cigarettes [not even a puff] in the 7 days before the 6-month follow-up
Measured: 6-months
Urge to smoke
urge to smoke using the Mood and Physical Symptoms Scale [MPSS] at baseline and 6 months; a higher score indicates a stronger urge to smoke; To assess the effect of abstinence calculate the change from baseline (just prior to stopping smoking) to the post-abstinence follow-up point for items 1 to 7 and 10 to 12, and take the raw scores for items 8 and 9
Measured: baseline and 6-months
Number of cigarettes smoked daily if still smoking
Number of cigarettes smoked daily if still smoking
Measured: 30 days, 56 days and 6 months
Time to first lapse
Time to first cigarette smoked after the initial quit, even a single puff
Measured: 6 months
Time to relapse
Time to return to regular smoking for three or more concurrent days after a period of abstinence.
Measured: 6 months
6 month continuous abstinence rate
Complete abstinence (smoking not more than 5 cigarettes) beginning on the quit date and lasting until the assessment at 6 months post-randomization with biochemical verification for those who report abstinence, using exhaled breath carbon monoxide (cut-off <10 ppm) measured with a carbon monoxide (CO) monitor.
*Cigarettes smoked within 5 days of randomization will be discounted.
Measured: 6-months
Wound complications
Seroma- wound drainage or repeated dressings required; Wound dehiscence or delayed wound healing
Measured: 6 months
Infectious complications
Infection - defined as a pathologic process caused by the invasion of normally sterile tissue, fluid, or body cavity by pathogenic or potentially pathogenic organisms.
Surgical site infection- An infection that occurs within 30 days after surgery and involves the skin, subcutaneous tissue of the incision (superficial incisional), or the deep soft tissue (e.g., fascia, muscle) of the incision (deep incisional).
Sepsis- Based on the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Sepsis requires a quick Sequential Organ Failure Assessment (qSOFA) Score ≥2 points due to infection. The qSOFA includes the following items and scoring system: 1. altered mental status (1 point); 2. systolic blood pressure ≤100 mm Hg (1 point); and 3. respiratory rate ≥22 breaths per minute (1 point).
Measured: 6 months
Respiratory complications
Pneumonia - defined as an acute infection of the pulmonary parenchyma that is associated with at least one sign or symptom of lower respiratory acute infection (e.g., cough, pleuritic chest pain) or acute systemic illness (e.g., fever, chills, confusion, hypoxemia); accompanied by the presence of an acute infiltrate/consolidation on a chest radiograph or auscultatory findings consistent with pneumonia (such as crackles and/or localized rales) for which there is no other explanation.
Respiratory insufficiency requiring ventilatory support - Patient intubated or put on bilevel positive airway pressure (BiPAP).
Measured: 6 months
Non-fatal Myocardial infarction
according to the 4th universal definition
Measured: 6 months
Number of Patients with Proximal venous thrombo-embolism
The diagnosis of PE requires any one of the following:
- A high probability ventilation/perfusion lung scan,
- An intraluminal filling defect of a segmental or larger artery on a helical computerized tomography (CT) scan,
- An intraluminal filling defect on pulmonary angiography, or
- A positive diagnostic test for deep venous thrombosis A. Non-diagnostic ventilation/perfusion lung scan B. Non-diagnostic helical CT scan.
The diagnosis of proximal DVT (leg or arm) requires:
- Thrombosis involving the popliteal vein or more proximal veins for leg DVT and axillary or more proximal veins for arm DVT, AND
- Evidence of vein thrombosis by any one of the following:
- A persistent intraluminal filling defect on contrast venography, 2. Non-compressibility of one or more venous segments on B mode compression ultrasonography, or 3. A clearly defined intraluminal filling defect on contrast enhanced computed tomography.
Measured: 6 months
Stroke
Stroke is defined as either: 1. a new focal neurological deficit thought to be vascular in origin with signs or symptoms lasting ≥24 hours or leading to death; or 2. a new focal neurological deficit thought to be vascular in origin with signs or symptoms lasting <24 hours with positive neuroimaging consistent with a stroke.
Measured: 6 months
Non-fatal cardiac arrest
Nonfatal cardiac arrest is defined as successful resuscitation from either documented or presumed ventricular fibrillation, sustained ventricular tachycardia, asystole, or pulseless electrical activity requiring cardiopulmonary resuscitation, pharmacological therapy, or cardiac defibrillation.
Measured: 6 months
Death
The definition of death is all cause mortality.
Measured: 6 months
Length of hospital stay
Defined as time of hospital admission to time of discharge from hospital after index surgery.
Measured: time of hospital admission to time of discharge for surgical stay
Acute hospital care since discharge
Acute-hospital care is a composite outcome of hospital re-admission (patient admission to an acute-care hospital) and emergency department visit (patient visit to an emergency department, which includes urgent-care centre visit).
Measured: after hospital discharge for the study surgery to 6-month follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Nov 2021
- Study start15 Jan 2024
- Primary completion1 Jul 2026 (estimated)
- Study completion1 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Smoking (Tobacco) AddictionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Model description
- 2x2 factorial
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 1,720 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Population Health Research Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Sandra Ofori, Dr., Principal investigator, Population Health Research InstituteFlavia Kessler Borges, Dr., Principal investigator, Population Health Research Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05102123
- Sponsor's protocol ID
- 2022_09_01
- Acronym
- PREVENT
- Status last verified
- Oct 2024
- First submitted
- 19 Oct 2021
- Last updated
- 3 Oct 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The Population Health Research Institute (PHRI) is the sponsor of this trial. The PHRI believes the dissemination of clinical research results is vital and sharing of data is important. PHRI prioritizes access to data analyses to researchers who have worked on the trial for a significant duration, have played substantial roles, and have participated in raising the funds to conduct the trial. PHRI balances the length of the research study, and the intellectual and financial investments that made it possible with the need to allow wider access to the data collected. Data will be disclosed only upon request and approval of the proposed use of the data by a Review Committee.
Study at a glance
From the registry record, last updated by the sponsor on 3 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PeRiopEratiVE SmokiNg CessaTion Trial
- ClinicalTrials.gov ID
- NCT05102123
- Acronym / sponsor ID
- PREVENT / 2022_09_01
- Conditions
- Smoking (Tobacco) Addiction, Smoking Cessation
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,720 participants (estimated)
- Lead sponsor
- Population Health Research InstituteUniversity, hospital or other
- Study start
- 15 Jan 2024 (actual)
- Primary completion
- 1 Jul 2026 (estimated)
- Study completion
- 1 Jan 2027 (estimated)
- First posted
- 1 Nov 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
PREVENT is a multicentre, 2x2 factorial, randomized clinical trial that aims to determine the effect of cytisine versus placebo, as well as the effect of video messaging to support smoking cessation versus standard of care in perioperative patients. This trial aims to investigate the effects of cytisine and text messaging on 6-month continuous abstinence rates. PREVENT will also assess secondary outcomes at 30 days, 56 days and 6 months post-randomization: 7-day point prevalence abstinence, urge to smoke, time to first lapse, time to relapse, number of cigarettes smoking if still smoking, pulmonary complications, vascular complications, wound and infectious complications, stroke, time in hospital and acute hospital care.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
- Model description
- 2x2 factorial
| Arm | Type | Receives |
|---|---|---|
| Cytisine and Video Messaging | Experimental | Drug: Cytisine, Behavioral: Video MessagingAdministration of cytisine (pharmaceutical support) to patients on a set dose schedule with behavioural support through video messaging. |
| Placebo and Video Messaging | Placebo comparator | Behavioral: Video MessagingAdministration of placebo (inactive drug) to patients on a set dose schedule with behavioural support through video messaging. |
| Cytisine and No Video Messaging | Active comparator | Drug: CytisineAdministration of cytisine (pharmaceutical support) to patients on a set dose schedule with behavioural support according to standard care such as a phone number for a self-help line. |
| Placebo and No Video Messaging | No intervention | –Administration of placebo (inactive drug) to patients on a set dose schedule behavioural support according to standard care such as a phone number for a self-help line. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- are ≥18 years of age
- are scheduled to undergo surgery within 28 days
- are a current smoker and not currently using any smoking cessation treatment and,
- have a smart mobile phone with an active, up to date data plan and with internet access
- provide informed consent to participate.
Key exclusion criteria (7 listed)
- are pregnant or breastfeeding or expecting to become pregnant during the study follow-up period
- are deemed unreliable for study procedures or follow-up
- have a documented allergic reaction to cytisine, or its components (non-medicinal ingredients) or to the non-medicinal ingredients of the placebo.
- had myocardial infarction, unstable angina, or stroke/transient ischemic attack within the preceding 2 weeks.
- will have surgery with expected nil intake by mouth for 2 or more days
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CytisineListed as a natural health product in Canada, cytisine is utilized to aid in smoking cessation | Drug | Cytisine and No Video Messaging, Cytisine and Video Messaging |
| Video MessagingSupportive messaging utilizing a video messaging platform to encourage patients to abstain from smoking throughout the treatment period. | Behavioural | Cytisine and Video Messaging, Placebo and Video Messaging |
Primary outcome
Smoking Cessation
Time frame: 6 months
complete abstinence (smoking not more than 5 cigarettes) beginning on day 5 post randomization and lasting until the assessment at 6 months post-randomization with biochemical verification for those who report abstinence, using exhaled breath carbon monoxide (cut-off <10 parts per million [ppm]) measured with a carbon monoxide (CO) monitor
18 secondary outcomes
7-day point-prevalence abstinence at 30 days
Time frame: 30 days
7-day point-prevalence abstinence at 56 days
Time frame: 56-days
7-day point-prevalence abstinence at 6-months
Time frame: 6-months
Urge to smoke
Time frame: baseline and 6-months
Number of cigarettes smoked daily if still smoking
Time frame: 30 days, 56 days and 6 months
Time to first lapse
Time frame: 6 months
Time to relapse
Time frame: 6 months
6 month continuous abstinence rate
Time frame: 6-months
Wound complications
Time frame: 6 months
Infectious complications
Time frame: 6 months
Respiratory complications
Time frame: 6 months
Non-fatal Myocardial infarction
Time frame: 6 months
Number of Patients with Proximal venous thrombo-embolism
Time frame: 6 months
Stroke
Time frame: 6 months
Non-fatal cardiac arrest
Time frame: 6 months
Death
Time frame: 6 months
Length of hospital stay
Time frame: time of hospital admission to time of discharge for surgical stay
Acute hospital care since discharge
Time frame: after hospital discharge for the study surgery to 6-month follow-up
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Oct 2024.
- Individual participant dataSharing planned: No. The Population Health Research Institute (PHRI) is the sponsor of this trial. The PHRI believes the dissemination of clinical research results is vital and sharing of data is important. PHRI prioritizes access to data analyses to researchers who have worked on the trial for a significant duration, have played substantial roles, and have participated in raising the funds to conduct the trial. PHRI balances the length of the research study, and the intellectual and financial investments that made it possible with the need to allow wider access to the data collected. Data will be disclosed only upon request and approval of the proposed use of the data by a Review Committee.
Related trials for Smoking (Tobacco) Addiction
Not yet recruiting
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
Asperger's Disorder, Asperger Disorder
RecruitingPhase 4
Addiction Potential of Very Low Nicotine Filtered Little Cigars
Smoking (Tobacco) Addiction
Active, not recruiting
THE EFFECT OF A TRANSTHEORETICAL MODEL-BASED CHATBOT SUPPORT INTERVENTION ON SMOKING BEHAVIOR IN UNIVERSITY STUDENTS
Smoking ( Cigarette), Smoking (Tobacco) Addiction
Recruiting
Interventional Study on Smoking Reduction in Psychiatry
Tobacco Addiction
Recruiting
Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)
Smoking Cessation, Nicotine Addiction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sandra Ofori, Dr. principal investigator
Population Health Research Institute
Flavia Kessler Borges, Dr. principal investigator
Population Health Research Institute
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Cytisine and Video Messaging in people with Smoking (Tobacco) Addiction and Smoking Cessation, run by Population Health Research Institute at 4 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 3 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Smoking Cessation (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Oct 2024.